Stock Yards Bank & Trust Co. Has $5.92 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Stock Yards Bank & Trust Co. decreased its position in Amgen Inc. (NASDAQ:AMGN) by 0.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 20,554 shares of the medical research company’s stock after selling 106 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Amgen were worth $5,920,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. OFI Invest Asset Management bought a new stake in shares of Amgen in the 3rd quarter worth $26,000. Briaud Financial Planning Inc bought a new stake in shares of Amgen in the 3rd quarter worth $26,000. BOK Financial Private Wealth Inc. bought a new stake in shares of Amgen in the 4th quarter worth $29,000. Providence Capital Advisors LLC bought a new stake in shares of Amgen in the 3rd quarter worth $30,000. Finally, Planned Solutions Inc. bought a new position in Amgen during the fourth quarter valued at about $30,000. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Oppenheimer restated an “outperform” rating and set a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. Truist Financial restated a “buy” rating and set a $320.00 price target on shares of Amgen in a research report on Friday, April 12th. Finally, The Goldman Sachs Group increased their price target on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Price Performance

Shares of Amgen stock traded up $3.70 on Monday, reaching $272.63. The stock had a trading volume of 780,994 shares, compared to its average volume of 2,831,551. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The company has a market cap of $146.23 billion, a P/E ratio of 21.53, a price-to-earnings-growth ratio of 2.50 and a beta of 0.58. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The business’s 50 day moving average is $276.90 and its two-hundred day moving average is $281.51.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The business had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. Amgen’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period last year, the firm posted $4.09 earnings per share. As a group, research analysts anticipate that Amgen Inc. will post 19.45 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.30%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.